BS_D144EJRQ
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 26.759999999999998
- os_event
- true
- age_years
- 2.085
- sex
- M
- race
- White
- new_clusters
- C1
- umap1_2d
- 3.850591854
- umap2_2d
- 0.625106709
- umap1_3d
- 0.151079755
- umap2_3d
- -2.54783286
- umap3_3d
- -0.710148745
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- TGF_BETA_SIGNALING+0.460
- INTERFERON_GAMMA_RESPONSE+0.440
- ANGIOGENESIS+0.430
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.390
- KRAS_SIGNALING_UP+0.370
- TNFA_SIGNALING_VIA_NFKB+0.360
- ALLOGRAFT_REJECTION+0.280
Top 10 suppressed
- E2F_TARGETS-0.430
- G2M_CHECKPOINT-0.380
- MITOTIC_SPINDLE-0.320
- SPERMATOGENESIS-0.220
- APICAL_SURFACE-0.170
- DNA_REPAIR-0.150
- PANCREAS_BETA_CELLS-0.120
- BILE_ACID_METABOLISM-0.110
- FATTY_ACID_METABOLISM-0.090
- HEDGEHOG_SIGNALING-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
0 twins match this tumor's tissue · 10 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_SQX5E15Z | pilocytic astrocytoma | — | 0.850 |
| 2 | BS_775HDFNY | pilocytic astrocytoma | — | 0.846 |
| 3 | BS_EN2VK7NY | low-grade glioma | — | 0.838 |
| 4 | SRR1410783 | GTEX | — | 0.838 |
| 5 | BS_N1E0H8YQ | low-grade glioma | — | 0.836 |
| 6 | BS_DEHJF4C7 | low-grade glioma | — | 0.836 |
| 7 | BS_42Y3YANN | pilocytic astrocytoma | — | 0.832 |
| 8 | BS_HX0S30NE | pilocytic astrocytoma | — | 0.830 |
| 9 | BS_Q2T9ZRM0 | Meningioma | — | 0.829 |
| 10 | BS_SXRS2P6T | low-grade glioma | — | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.460 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |